Posters
ESMO Immuno-Oncology Congress 2025
First-in-human evaluation of CDR404, a MAGE-A4–targeted T cell engager, in ovarian cancer: pharmacodynamic and clinical activity findings from early dose cohorts
CONTRIBUTORS:
Kristoffer Rohrberg, Matteo Morotti, Giuseppe Curigliano, Rom Leidner, Mark Diamond, Nikolina Vachtsevanou, Christian Leisner, Sarah Holland, Leonardo Borras, Daniel Lenherr-Frey, Melissa Vrohlings, Swethajit Biswas
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting
Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager
CONTRIBUTORS:
Melissa Vrohlings, Matteo Morotti, Daniel Lenherr – Frey, Nikolina Vachtsevanou, Clare Price, Leonardo Borras, Rouven Bingel – Erlenmeyer, Paul Swiecicki, Coral Olazagasti, Rom Leidner, Mark Diamond, Kristoffer Rohrberg, Sylvie Rottey, Hans Prenen, Jean – Pascal H Machiels, Nuria Kotecki, Alberto Hernando Calvo, Guillermo de Velasco, Guillermo Suay Montagud, Roda Perez Desamparados, Juan Jesús Martin, Matteo Simonelli, Curigliano Giuseppe, Christian Leisner, Swethajit Biswas, Emiliano Calvo Aller
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Meeting
CDR609: A First-in-Class LGR5-targeted T Cell Engager for Treatment of Colorectal
Cancer and Other Solid Tumors
CONTRIBUTORS:
Athanasia Dasargyri, Sophie Barsin, Fabian Scheifele, Philipp Richle, Nagjie Alijaj, Anna Sobieraj, Romina Doerig, Hannes Merten, Philip Knobel, Martina Priola , Blaz Pavlovic, Marko Keric, David Schurter, Cedric Kiss, Ariadna Vilarrasa, Stephanie Jungmichel, Matteo Morotti, Swethajit Biswas, Christian Leisner, Leonardo Borras
AACR Annual Meeting 2025
A novel T cell engager antibody for the treatment of HLA-A*01/KK-LC-1-positive tumors
CONTRIBUTORS:
Athanasia Dasargyri, Melissa Vrohlings, Stephanie Jungmichel, Blaz Pavlovic, Martina Priola, Zoi Barou, Hannes Merten, Philip Knobel, Luca Scheu, Romina Dörig, Fabian Scheifele, Philipp Richle, Daniel Kuhn, Gonzalo Acuña, Matteo Morotti
AACR Annual Meeting 2025
Durable and potent in vitro T cell activity with repeated exposure to CDR404; a potential best-in-class T cell engager targeting MAGE-A4
CONTRIBUTORS:
Alessio Vantellini, Nora Wettstein, Melissa Vrohlings, Stephanie Jungmichel, André Fonseca, Alice Langer, Anna Howald, Zoi Barou, Daniel Lenherr-Frey, Matteo Morotti, Christian Leisner, Swethajit Biswas, Leonardo Borras